Sun Pharmaceutical Industries (Sun Pharma) said that one of its fully-owned subsidiaries has launched the generic version of Pfizer-developed Palbociclib in India for patients with advanced breast cancer.

The Indian pharma company will make the anti-cancer drug available under the brand name PALENO (Palbociclib) 75 mg, 100 mg, and 125 mg.

Palbociclib has approval in the US, European Union, and India in combination with hormonal therapies for patients having hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer which is locally advanced or metastatic.

Kirti Ganorkar — Sun Pharma India business CEO said: “We are introducing Palbociclib at an affordable price which will help improve patient access. PALENOTM will address the treatment need of several advanced breast cancer patients in India. For the first time, we are introducing a unique patient assistance program that will improve patient compliance and accessibility.”

  Breast Cancer, cancer, India, Kirti Ganorkar, palbociclib, Pfizer, Sun Pharma, Sun Pharmaceutical Industries